LEX Diagnostics

LEX Diagnostics is a molecular diagnostics company developing rapid point-of-care PCR testing through its proprietary thermal cycling platform.

Its system delivers quantitative PCR results directly from a dry swab in six to ten minutes with no sample preparation, targeting respiratory infections including influenza and COVID-19. The system received FDA 510(k) clearance and CLIA waiver in 2026.

A subsidiary of TTP Group, LEX Diagnostics is based at Melbourn Science Park.